These innovative molecules represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose levels. https://dianejbgv304908.blogzet.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-53886350